Rationale and trial design of bardoxolone methyl evaluation in patients with chronic kidney disease and type 2 diabetes: The occurrence of renal events (BEACON)
Journal article
Zeeuw, Dick de, Akizawa, Tadao, Agarwal, Rajiv, Audhya, Paul, Bakris, George L., Chin, Melanie P., Krauth, Melissa, Lambers Heerspink, Hiddo J., Meyer, Colin J., McMurray, John J.V., Parving, Hans-Henrick, Pergola, Pablo E., Remuzzi, Guiseppe, Toto, Robert D., Vaziri, Nosratola D., Wanner, Christoph, Warnock, David G., Wittes, Janet T. and Chertow, Glenn M.. (2013). Rationale and trial design of bardoxolone methyl evaluation in patients with chronic kidney disease and type 2 diabetes: The occurrence of renal events (BEACON). American Journal of Nephrology. 37(3), pp. 212 - 222. https://doi.org/10.1159/000346948
Authors | Zeeuw, Dick de, Akizawa, Tadao, Agarwal, Rajiv, Audhya, Paul, Bakris, George L., Chin, Melanie P., Krauth, Melissa, Lambers Heerspink, Hiddo J., Meyer, Colin J., McMurray, John J.V., Parving, Hans-Henrick, Pergola, Pablo E., Remuzzi, Guiseppe, Toto, Robert D., Vaziri, Nosratola D., Wanner, Christoph, Warnock, David G., Wittes, Janet T. and Chertow, Glenn M. |
---|---|
Abstract | Chronic kidney disease ( CKD ) associated with type 2 diabetes mellitus constitutes a global epidemic complicated by considerable renal and cardiovascular morbidity and mortality, despite the provision of inhibitors of the renin-angiotensin-aldosterone system ( RAAS ). Bardoxolone methyl, a synthetic triterpenoid that reduces oxidative stress and inflammation through Nrf2 activation and inhibition of NF-κB was previously shown to increase estimated glomerular filtration rate ( eGFR ) in patients with CKD associated with type 2 diabetes mellitus. To date, no antioxidant or anti-inflammatory therapy has proved successful at slowing the progression of CKD. |
Keywords | Clinical trial; trial design; bardoxolone methyl; nrf2; end-stage renal disease; cardiovascular death; chronic kidney disease; Diabetes mellitus; glomerular filtration rate |
Year | 2013 |
Journal | American Journal of Nephrology |
Journal citation | 37 (3), pp. 212 - 222 |
Publisher | S. Karger AG |
ISSN | 0250-8095 |
Digital Object Identifier (DOI) | https://doi.org/10.1159/000346948 |
Scopus EID | 2-s2.0-84874615691 |
Page range | 212 - 222 |
Research Group | Mary MacKillop Institute for Health Research |
Publisher's version | File Access Level Controlled |
Place of publication | Switzerland |
https://acuresearchbank.acu.edu.au/item/88z83/rationale-and-trial-design-of-bardoxolone-methyl-evaluation-in-patients-with-chronic-kidney-disease-and-type-2-diabetes-the-occurrence-of-renal-events-beacon
Restricted files
Publisher's version
101
total views0
total downloads0
views this month0
downloads this month